Previous 10 | Next 10 |
home / stock / vphif / vphif news
(NewsDirect) Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) CEO Steve Saviuk joined Proactive's Stephen Gunnion to discuss the company's strong position on the Globe and Mail's Report on Business annual list of Canada’s top-growing companies. The company placed 151 out of 425 com...
VALEO PHARMA MAKES THE LIST OF THE GLOBE AND MAIL'S FIFTH-ANNUAL RANKING OF CANADA'S TOP GROWING COMPANIES Canada NewsWire MONTREAL , Oct. 4, 2023 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadi...
(NewsDirect) Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share details the company has entered into a credit facility agreement with Accord Financial for a total of $5 million. The credit facility, backed by a first-ranking lien on the company's short-term ass...
VALEO PHARMA ENTERS INTO $5 MILLION CREDIT FACILITY AGREEMENT WITH ACCORD FINANCIAL INC. Canada NewsWire MONTREAL , Sept. 27, 2023 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE:VP2) (" Valeo " or the " Company "), a Canadian pharmaceu...
(NewsDirect) Valeo Pharma CEO Steve Saviuk joined Proactive's Steve Darling to share news regarding the company's strong third-quarter performance. The company has once again shattered its own records, demonstrating remarkable growth in various key areas of its business. In 3Q 202...
VALEO PHARMA REPORTS RECORD THIRD QUARTER 2023 REVENUES Canada NewsWire Seventh consecutive quarter of revenue growth at $14.1 million in Q3-23, up 132% over Q3-22. Physicians prescribing Enerzair and Atectura reached 2,503 at the end of Q3-23, representing a 23%...
VALEO PHARMA TO HOST THIRD QUARTER 2023 RESULTS CONFERENCE CALL / WEBCAST Canada NewsWire MONTREAL , Sept. 7, 2023 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, annou...
VALEO PHARMA CLOSES $4.5 MILLION FINANCING Canada NewsWire $3.92 million raised from non-brokered private placement offering, and $0.58 million from insider loan Investissement Québec and insiders each invest $2.0 million Proceeds fro...
VALEO PHARMA PROVIDES UPDATE ON OPHTHALMOLOGY BUSINESS UNIT Canada NewsWire Novartis agrees to sell global rights to XIIDRA® and several other ophthalmology products to Baucsh + Lomb SIMBRINZA® not included in the divestiture MONTREAL , ...
VALEO PHARMA ANNOUNCES NEW BOARD APPOINTMENTS Canada NewsWire MONTREAL , June 22, 2023 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today announced that Ms. Tamara...
News, Short Squeeze, Breakout and More Instantly...
VALEO PHARMA ANNOUNCES SENIOR EXECUTIVE APPOINTMENT AND BOARD OF DIRECTORS CHANGE Canada NewsWire MONTREAL , June 18, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical compan...
(NewsDirect) Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to discuss the company's financial results for the second quarter, which saw record-breaking revenue for the period. The company reported revenues of $14.1 million for Q2, an increase from the $13.6 million rec...
VALEO PHARMA ANNOUNCES RESTRUCTURING OF COMMERCIAL FIELD OPERATIONS TO SUPPORT PATH TO PROFITABILITY Canada NewsWire Changes to respiratory business unit to generate more than $5 million in annual savings Follows previously announced cost saving measures exce...